MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call

Rhea-AI Summary

MacroGenics, a biopharmaceutical firm specializing in monoclonal antibody-based therapeutics for cancer treatment, will announce its second-quarter 2022 financial results on August 8, 2022, after market closure. A conference call to discuss these results and corporate progress will follow at 4:30 PM ET on the same day. Interested participants can register for the call and access a webcast on the company's Investor Relations website. MacroGenics aims to leverage its innovative technology platforms to develop promising therapeutics and engage in strategic collaborations.

Positive

• Company specializes in innovative monoclonal antibody-based therapeutics.
• Focus on cancer treatment through proprietary technology platforms.
• Opportunity for stakeholders to engage in financial discussions via conference call.

Negative

• None.

ROCKVILLE, MD, July 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter of 2022 after the market closes on Monday, August 8, 2022.  MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Monday, August 8, 2022, at 4:30 pm ET.

Conference Call Information

To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.

About MacroGenics, Inc.

MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

FAQ

When will MacroGenics release its financial results for Q2 2022?

MacroGenics will release its financial results for the second quarter of 2022 after the market closes on August 8, 2022.

What time is the conference call for MacroGenics Q2 2022 results?

The conference call to discuss the Q2 2022 results is scheduled for August 8, 2022, at 4:30 PM ET.

How can I participate in the MacroGenics conference call?

To participate in the MacroGenics conference call, you need to register in advance via the link provided in the press release.

Where can I access the webcast of the MacroGenics conference call?

The webcast of the MacroGenics conference call can be accessed under the 'Events & Presentations' section of the Investor Relations website.

What is the focus area of MacroGenics as a biopharmaceutical company?

MacroGenics focuses on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer.